Current developments in gastric cancer: from molecular profiling to treatment strategy
M Alsina, V Arrazubi, M Diez, J Tabernero - … Reviews Gastroenterology & …, 2023 - nature.com
Gastric cancer and gastro-oesophageal junction cancer represent a global health-care
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …
challenge. Despite the efficacy of improved chemotherapy and surgical options, these …
Gastric cancer: epidemiology, risk factors, classification, genomic characteristics and treatment strategies
Gastric cancer (GC) is one of the most common malignancies worldwide and it is the fourth
leading cause of cancer-related death. GC is a multifactorial disease, where both …
leading cause of cancer-related death. GC is a multifactorial disease, where both …
Gastric cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up☆
More than 1 million (1 089 103) new cases of gastric cancer were estimated globally in
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …
2020, resulting in 768 793 deaths. 1 These burden estimates will continue to increase due to …
Wnt/beta-catenin signaling confers ferroptosis resistance by targeting GPX4 in gastric cancer
Y Wang, L Zheng, W Shang, Z Yang, T Li… - Cell Death & …, 2022 - nature.com
The development of chemotherapy resistance is the most vital obstacle to clinical efficacy in
gastric cancer (GC). The dysregulation of the Wnt/beta-catenin signaling pathway is critically …
gastric cancer (GC). The dysregulation of the Wnt/beta-catenin signaling pathway is critically …
Signaling pathways and therapeutic interventions in gastric cancer
ZN Lei, QX Teng, Q Tian, W Chen, Y ** the genomic diaspora of gastric cancer
Gastric cancer (GC) is a leading contributor to global cancer incidence and mortality.
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …
Pioneering genomic studies, focusing largely on primary GCs, revealed driver alterations in …
Biomarker-targeted therapies for advanced-stage gastric and gastro-oesophageal junction cancers: an emerging paradigm
Y Nakamura, A Kawazoe, F Lordick… - Nature reviews Clinical …, 2021 - nature.com
Advances in cancer biology and sequencing technology have enabled the selection of
targeted and more effective treatments for individual patients with various types of solid …
targeted and more effective treatments for individual patients with various types of solid …